AbbVie to buy ImmunoGen for $10.1 billion to boost cancer drug portfolio
AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, boosting its presence in the market
1970-01-01 08:00
AbbVie trims full-year profit forecast on higher R&D expenses
(Reuters) -AbbVie Inc cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development
1970-01-01 08:00
US FDA approves Genmab-AbbVie's blood cancer therapy
(Reuters) -The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult
1970-01-01 08:00